ASH 2019 | CLL: relapsed disease, discontinuation and MRD
Barbara Eichhorst
• 7 Dec 2019
Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, discusses relapsed disease, treatment discontinuation and MRD in chronic lymphocytic leukemia (CLL), highlighting observations from the MURANO trial (NCT02005471). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
